In vivo31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK 506

Seiichi Suzuki, Masaru Kanashiro, Ryosuke Hayashi, Takashi Kenmochi, Toshiyuki Fukuoka, Hiroshi Amemiya

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Administration of FK506 for 15 days at daily doses of 3.2 mg/kg p.o., 10 mg/kg p.o., 0.32 mg/kg i.m., or 1 mg/kg i.m. to heart-allografted rats resulted in a significant prolongation of graft survival time. The best graft acceptance was obtained in the 1 mg/kg i.m. group: all six grafts survived longer than 50 days, and two of them, indefinitely. The31P nuclear magnetic resonance (NMR) technique was utilized to investigate in vivo the energy metabolism of grafts. The ratios of inorganic phosphate (Pi)/phosphocreatine (PCr) and PCr/ATP were useful parameters for monitoring cardiac insufficiency after transplantation. The mean ratios of Pi/PCr and PCr/ATP in syngeneic grafts were 0.38±0.11 and 1.88±0.42, respectively. In the control allografts, a rapid increase in the Pi/PCr ratio and a decrease in the PCr/ATP ratio were found from day 5. During the period of FK 506 administration, increased Pi/PCr and decreased PCr/ATP ratios were also observed in all groups. The changes in these ratios were related with FK506 dosage. The results suggest that FK506 has a side-effect on graft metabolism. The metabolism tended to improve upon cessation of the drug in all grafts, but it worsened again in 3-3 1/2 weeks in the rats treated with 3.2 mg/kg p.o., 10 mg/kg p.o., or 0.32 mg/kg i.m. This seemed to be due to graft rejection. In the 1 mg/kg i.m. group, lowering of the Pi/PCr ratio and elevation of the PCr/ATP ratio were observed after the withdrawal of FK506, and these ratios remained stable until the end of the observation period. In conclusion, FK506 was found to be a potent immunosuppressant with a significant side-effect on graft metabolism.

Original languageEnglish
Pages (from-to)224-229
Number of pages6
JournalHeart and Vessels
Volume5
Issue number4
DOIs
Publication statusPublished - 01-12-1990

Fingerprint

Phosphocreatine
Tacrolimus
Immunosuppressive Agents
Magnetic Resonance Spectroscopy
Transplants
Adenosine Triphosphate
Graft Rejection
Graft Survival
Energy Metabolism
Allografts
Transplantation
Phosphates
Observation

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Suzuki, Seiichi ; Kanashiro, Masaru ; Hayashi, Ryosuke ; Kenmochi, Takashi ; Fukuoka, Toshiyuki ; Amemiya, Hiroshi. / In vivo31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK 506. In: Heart and Vessels. 1990 ; Vol. 5, No. 4. pp. 224-229.
@article{d69cec531ef8457c9b767a99346cd947,
title = "In vivo31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK 506",
abstract = "Administration of FK506 for 15 days at daily doses of 3.2 mg/kg p.o., 10 mg/kg p.o., 0.32 mg/kg i.m., or 1 mg/kg i.m. to heart-allografted rats resulted in a significant prolongation of graft survival time. The best graft acceptance was obtained in the 1 mg/kg i.m. group: all six grafts survived longer than 50 days, and two of them, indefinitely. The31P nuclear magnetic resonance (NMR) technique was utilized to investigate in vivo the energy metabolism of grafts. The ratios of inorganic phosphate (Pi)/phosphocreatine (PCr) and PCr/ATP were useful parameters for monitoring cardiac insufficiency after transplantation. The mean ratios of Pi/PCr and PCr/ATP in syngeneic grafts were 0.38±0.11 and 1.88±0.42, respectively. In the control allografts, a rapid increase in the Pi/PCr ratio and a decrease in the PCr/ATP ratio were found from day 5. During the period of FK 506 administration, increased Pi/PCr and decreased PCr/ATP ratios were also observed in all groups. The changes in these ratios were related with FK506 dosage. The results suggest that FK506 has a side-effect on graft metabolism. The metabolism tended to improve upon cessation of the drug in all grafts, but it worsened again in 3-3 1/2 weeks in the rats treated with 3.2 mg/kg p.o., 10 mg/kg p.o., or 0.32 mg/kg i.m. This seemed to be due to graft rejection. In the 1 mg/kg i.m. group, lowering of the Pi/PCr ratio and elevation of the PCr/ATP ratio were observed after the withdrawal of FK506, and these ratios remained stable until the end of the observation period. In conclusion, FK506 was found to be a potent immunosuppressant with a significant side-effect on graft metabolism.",
author = "Seiichi Suzuki and Masaru Kanashiro and Ryosuke Hayashi and Takashi Kenmochi and Toshiyuki Fukuoka and Hiroshi Amemiya",
year = "1990",
month = "12",
day = "1",
doi = "10.1007/BF02058694",
language = "English",
volume = "5",
pages = "224--229",
journal = "Heart and Vessels",
issn = "0910-8327",
publisher = "Springer Japan",
number = "4",

}

In vivo31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK 506. / Suzuki, Seiichi; Kanashiro, Masaru; Hayashi, Ryosuke; Kenmochi, Takashi; Fukuoka, Toshiyuki; Amemiya, Hiroshi.

In: Heart and Vessels, Vol. 5, No. 4, 01.12.1990, p. 224-229.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vivo31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK 506

AU - Suzuki, Seiichi

AU - Kanashiro, Masaru

AU - Hayashi, Ryosuke

AU - Kenmochi, Takashi

AU - Fukuoka, Toshiyuki

AU - Amemiya, Hiroshi

PY - 1990/12/1

Y1 - 1990/12/1

N2 - Administration of FK506 for 15 days at daily doses of 3.2 mg/kg p.o., 10 mg/kg p.o., 0.32 mg/kg i.m., or 1 mg/kg i.m. to heart-allografted rats resulted in a significant prolongation of graft survival time. The best graft acceptance was obtained in the 1 mg/kg i.m. group: all six grafts survived longer than 50 days, and two of them, indefinitely. The31P nuclear magnetic resonance (NMR) technique was utilized to investigate in vivo the energy metabolism of grafts. The ratios of inorganic phosphate (Pi)/phosphocreatine (PCr) and PCr/ATP were useful parameters for monitoring cardiac insufficiency after transplantation. The mean ratios of Pi/PCr and PCr/ATP in syngeneic grafts were 0.38±0.11 and 1.88±0.42, respectively. In the control allografts, a rapid increase in the Pi/PCr ratio and a decrease in the PCr/ATP ratio were found from day 5. During the period of FK 506 administration, increased Pi/PCr and decreased PCr/ATP ratios were also observed in all groups. The changes in these ratios were related with FK506 dosage. The results suggest that FK506 has a side-effect on graft metabolism. The metabolism tended to improve upon cessation of the drug in all grafts, but it worsened again in 3-3 1/2 weeks in the rats treated with 3.2 mg/kg p.o., 10 mg/kg p.o., or 0.32 mg/kg i.m. This seemed to be due to graft rejection. In the 1 mg/kg i.m. group, lowering of the Pi/PCr ratio and elevation of the PCr/ATP ratio were observed after the withdrawal of FK506, and these ratios remained stable until the end of the observation period. In conclusion, FK506 was found to be a potent immunosuppressant with a significant side-effect on graft metabolism.

AB - Administration of FK506 for 15 days at daily doses of 3.2 mg/kg p.o., 10 mg/kg p.o., 0.32 mg/kg i.m., or 1 mg/kg i.m. to heart-allografted rats resulted in a significant prolongation of graft survival time. The best graft acceptance was obtained in the 1 mg/kg i.m. group: all six grafts survived longer than 50 days, and two of them, indefinitely. The31P nuclear magnetic resonance (NMR) technique was utilized to investigate in vivo the energy metabolism of grafts. The ratios of inorganic phosphate (Pi)/phosphocreatine (PCr) and PCr/ATP were useful parameters for monitoring cardiac insufficiency after transplantation. The mean ratios of Pi/PCr and PCr/ATP in syngeneic grafts were 0.38±0.11 and 1.88±0.42, respectively. In the control allografts, a rapid increase in the Pi/PCr ratio and a decrease in the PCr/ATP ratio were found from day 5. During the period of FK 506 administration, increased Pi/PCr and decreased PCr/ATP ratios were also observed in all groups. The changes in these ratios were related with FK506 dosage. The results suggest that FK506 has a side-effect on graft metabolism. The metabolism tended to improve upon cessation of the drug in all grafts, but it worsened again in 3-3 1/2 weeks in the rats treated with 3.2 mg/kg p.o., 10 mg/kg p.o., or 0.32 mg/kg i.m. This seemed to be due to graft rejection. In the 1 mg/kg i.m. group, lowering of the Pi/PCr ratio and elevation of the PCr/ATP ratio were observed after the withdrawal of FK506, and these ratios remained stable until the end of the observation period. In conclusion, FK506 was found to be a potent immunosuppressant with a significant side-effect on graft metabolism.

UR - http://www.scopus.com/inward/record.url?scp=0025195678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025195678&partnerID=8YFLogxK

U2 - 10.1007/BF02058694

DO - 10.1007/BF02058694

M3 - Article

C2 - 1699922

AN - SCOPUS:0025195678

VL - 5

SP - 224

EP - 229

JO - Heart and Vessels

JF - Heart and Vessels

SN - 0910-8327

IS - 4

ER -